nodes	percent_of_prediction	percent_of_DWPC	metapath
Phenylpropanolamine—L-Phenylalanine—Melphalan—breast cancer	0.39	1	CrCrCtD
Phenylpropanolamine—CYP1A2—Anastrozole—breast cancer	0.0713	0.401	CbGbCtD
Phenylpropanolamine—CYP1A2—Toremifene—breast cancer	0.0652	0.367	CbGbCtD
Phenylpropanolamine—CYP1A2—Tamoxifen—breast cancer	0.0238	0.134	CbGbCtD
Phenylpropanolamine—CYP1A2—Fluorouracil—breast cancer	0.0176	0.0987	CbGbCtD
Phenylpropanolamine—Pseudoephedrine—IL2—breast cancer	0.00145	0.214	CrCbGaD
Phenylpropanolamine—Ephedrine—ACHE—breast cancer	0.00113	0.167	CrCbGaD
Phenylpropanolamine—Ephedrine—BCHE—breast cancer	0.000665	0.0983	CrCbGaD
Phenylpropanolamine—Dizziness—Raloxifene—breast cancer	0.000561	0.00257	CcSEcCtD
Phenylpropanolamine—Irritability—Capecitabine—breast cancer	0.000561	0.00257	CcSEcCtD
Phenylpropanolamine—Hypotension—Melphalan—breast cancer	0.00056	0.00256	CcSEcCtD
Phenylpropanolamine—Urinary retention—Capecitabine—breast cancer	0.000559	0.00256	CcSEcCtD
Phenylpropanolamine—Dyskinesia—Doxorubicin—breast cancer	0.000556	0.00254	CcSEcCtD
Phenylpropanolamine—Insomnia—Tamoxifen—breast cancer	0.000554	0.00253	CcSEcCtD
Phenylpropanolamine—Ataxia—Capecitabine—breast cancer	0.000553	0.00253	CcSEcCtD
Phenylpropanolamine—Hypotension—Goserelin—breast cancer	0.000546	0.0025	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Tamoxifen—breast cancer	0.000546	0.00249	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Irinotecan—breast cancer	0.000543	0.00248	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Mitoxantrone—breast cancer	0.000543	0.00248	CcSEcCtD
Phenylpropanolamine—Vomiting—Idarubicin—breast cancer	0.00054	0.00247	CcSEcCtD
Phenylpropanolamine—Vomiting—Raloxifene—breast cancer	0.00054	0.00247	CcSEcCtD
Phenylpropanolamine—Constipation—Vinblastine—breast cancer	0.000539	0.00246	CcSEcCtD
Phenylpropanolamine—Rash—Raloxifene—breast cancer	0.000535	0.00245	CcSEcCtD
Phenylpropanolamine—Rash—Idarubicin—breast cancer	0.000535	0.00245	CcSEcCtD
Phenylpropanolamine—Dermatitis—Idarubicin—breast cancer	0.000535	0.00244	CcSEcCtD
Phenylpropanolamine—Dermatitis—Raloxifene—breast cancer	0.000535	0.00244	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Melphalan—breast cancer	0.000534	0.00244	CcSEcCtD
Phenylpropanolamine—Coordination abnormal—Doxorubicin—breast cancer	0.000532	0.00243	CcSEcCtD
Phenylpropanolamine—Nausea—Anastrozole—breast cancer	0.000531	0.00243	CcSEcCtD
Phenylpropanolamine—Nausea—Letrozole—breast cancer	0.000531	0.00243	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Gemcitabine—breast cancer	0.000529	0.00242	CcSEcCtD
Phenylpropanolamine—Insomnia—Goserelin—breast cancer	0.000529	0.00242	CcSEcCtD
Phenylpropanolamine—Constipation—Tamoxifen—breast cancer	0.000523	0.00239	CcSEcCtD
Phenylpropanolamine—Hepatocellular injury—Doxorubicin—breast cancer	0.000522	0.00239	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Goserelin—breast cancer	0.000521	0.00238	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Fluorouracil—breast cancer	0.00052	0.00238	CcSEcCtD
Phenylpropanolamine—Anxiety—Thiotepa—breast cancer	0.00052	0.00238	CcSEcCtD
Phenylpropanolamine—Somnolence—Goserelin—breast cancer	0.00052	0.00238	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Vinblastine—breast cancer	0.000519	0.00237	CcSEcCtD
Phenylpropanolamine—Tachycardia—Vinorelbine—breast cancer	0.000511	0.00234	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Chlorambucil—breast cancer	0.000507	0.00232	CcSEcCtD
Phenylpropanolamine—Nausea—Raloxifene—breast cancer	0.000504	0.00231	CcSEcCtD
Phenylpropanolamine—Nausea—Idarubicin—breast cancer	0.000504	0.00231	CcSEcCtD
Phenylpropanolamine—Confusional state—Thiotepa—breast cancer	0.000504	0.0023	CcSEcCtD
Phenylpropanolamine—Constipation—Goserelin—breast cancer	0.0005	0.00229	CcSEcCtD
Phenylpropanolamine—Vision blurred—Mitoxantrone—breast cancer	0.000499	0.00228	CcSEcCtD
Phenylpropanolamine—Hypotension—Vinorelbine—breast cancer	0.000489	0.00224	CcSEcCtD
Phenylpropanolamine—Pseudoephedrine—TNF—breast cancer	0.000489	0.0723	CrCbGaD
Phenylpropanolamine—Tachycardia—Thiotepa—breast cancer	0.000488	0.00223	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Goserelin—breast cancer	0.000482	0.0022	CcSEcCtD
Phenylpropanolamine—Vision blurred—Fluorouracil—breast cancer	0.000478	0.00218	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Vinorelbine—breast cancer	0.000467	0.00213	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Vinblastine—breast cancer	0.000464	0.00212	CcSEcCtD
Phenylpropanolamine—Flushing—Paclitaxel—breast cancer	0.00046	0.0021	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Tamoxifen—breast cancer	0.000451	0.00206	CcSEcCtD
Phenylpropanolamine—Anxiety—Mitoxantrone—breast cancer	0.000449	0.00205	CcSEcCtD
Phenylpropanolamine—Constipation—Vinorelbine—breast cancer	0.000448	0.00205	CcSEcCtD
Phenylpropanolamine—Somnolence—Thiotepa—breast cancer	0.000445	0.00203	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Paclitaxel—breast cancer	0.000443	0.00202	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Melphalan—breast cancer	0.000442	0.00202	CcSEcCtD
Phenylpropanolamine—Vomiting—Chlorambucil—breast cancer	0.000437	0.002	CcSEcCtD
Phenylpropanolamine—Confusional state—Irinotecan—breast cancer	0.000435	0.00199	CcSEcCtD
Phenylpropanolamine—Confusional state—Mitoxantrone—breast cancer	0.000435	0.00199	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Vinorelbine—breast cancer	0.000431	0.00197	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Goserelin—breast cancer	0.000431	0.00197	CcSEcCtD
Phenylpropanolamine—Constipation—Thiotepa—breast cancer	0.000428	0.00195	CcSEcCtD
Phenylpropanolamine—Tension—Paclitaxel—breast cancer	0.000423	0.00194	CcSEcCtD
Phenylpropanolamine—Tachycardia—Mitoxantrone—breast cancer	0.000421	0.00193	CcSEcCtD
Phenylpropanolamine—Nervousness—Paclitaxel—breast cancer	0.000419	0.00192	CcSEcCtD
Phenylpropanolamine—Irritability—Methotrexate—breast cancer	0.000418	0.00191	CcSEcCtD
Phenylpropanolamine—Confusional state—Fluorouracil—breast cancer	0.000417	0.00191	CcSEcCtD
Phenylpropanolamine—Dizziness—Vinblastine—breast cancer	0.000417	0.0019	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Thiotepa—breast cancer	0.000412	0.00188	CcSEcCtD
Phenylpropanolamine—Ataxia—Methotrexate—breast cancer	0.000412	0.00188	CcSEcCtD
Phenylpropanolamine—Nausea—Chlorambucil—breast cancer	0.000408	0.00187	CcSEcCtD
Phenylpropanolamine—Vision blurred—Paclitaxel—breast cancer	0.000407	0.00186	CcSEcCtD
Phenylpropanolamine—Dizziness—Tamoxifen—breast cancer	0.000405	0.00185	CcSEcCtD
Phenylpropanolamine—Tremor—Paclitaxel—breast cancer	0.000404	0.00185	CcSEcCtD
Phenylpropanolamine—Tachycardia—Fluorouracil—breast cancer	0.000404	0.00185	CcSEcCtD
Phenylpropanolamine—Hypotension—Mitoxantrone—breast cancer	0.000404	0.00184	CcSEcCtD
Phenylpropanolamine—Hypotension—Irinotecan—breast cancer	0.000404	0.00184	CcSEcCtD
Phenylpropanolamine—Vomiting—Vinblastine—breast cancer	0.000401	0.00183	CcSEcCtD
Phenylpropanolamine—Agitation—Paclitaxel—breast cancer	0.000397	0.00181	CcSEcCtD
Phenylpropanolamine—Hypotension—Gemcitabine—breast cancer	0.000393	0.0018	CcSEcCtD
Phenylpropanolamine—Insomnia—Irinotecan—breast cancer	0.000391	0.00179	CcSEcCtD
Phenylpropanolamine—Flushing—Docetaxel—breast cancer	0.00039	0.00178	CcSEcCtD
Phenylpropanolamine—Vomiting—Tamoxifen—breast cancer	0.000389	0.00178	CcSEcCtD
Phenylpropanolamine—Dizziness—Goserelin—breast cancer	0.000387	0.00177	CcSEcCtD
Phenylpropanolamine—Hypotension—Fluorouracil—breast cancer	0.000386	0.00177	CcSEcCtD
Phenylpropanolamine—Rash—Tamoxifen—breast cancer	0.000386	0.00176	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Vinorelbine—breast cancer	0.000386	0.00176	CcSEcCtD
Phenylpropanolamine—Dermatitis—Tamoxifen—breast cancer	0.000386	0.00176	CcSEcCtD
Phenylpropanolamine—Ataxia—Epirubicin—breast cancer	0.000385	0.00176	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Irinotecan—breast cancer	0.000385	0.00176	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Mitoxantrone—breast cancer	0.000385	0.00176	CcSEcCtD
Phenylpropanolamine—Somnolence—Mitoxantrone—breast cancer	0.000384	0.00175	CcSEcCtD
Phenylpropanolamine—Somnolence—Irinotecan—breast cancer	0.000384	0.00175	CcSEcCtD
Phenylpropanolamine—Vomiting—Melphalan—breast cancer	0.000381	0.00174	CcSEcCtD
Phenylpropanolamine—Insomnia—Gemcitabine—breast cancer	0.00038	0.00174	CcSEcCtD
Phenylpropanolamine—Benzyl alcohol—CYP1A1—breast cancer	0.000378	0.0559	CrCbGaD
Phenylpropanolamine—Rash—Melphalan—breast cancer	0.000378	0.00173	CcSEcCtD
Phenylpropanolamine—Flushing—Capecitabine—breast cancer	0.000378	0.00173	CcSEcCtD
Phenylpropanolamine—Dermatitis—Melphalan—breast cancer	0.000378	0.00173	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Docetaxel—breast cancer	0.000375	0.00172	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Gemcitabine—breast cancer	0.000375	0.00171	CcSEcCtD
Phenylpropanolamine—Nausea—Vinblastine—breast cancer	0.000374	0.00171	CcSEcCtD
Phenylpropanolamine—Insomnia—Fluorouracil—breast cancer	0.000374	0.00171	CcSEcCtD
Phenylpropanolamine—Somnolence—Gemcitabine—breast cancer	0.000374	0.00171	CcSEcCtD
Phenylpropanolamine—Vomiting—Goserelin—breast cancer	0.000372	0.0017	CcSEcCtD
Phenylpropanolamine—Constipation—Irinotecan—breast cancer	0.000369	0.00169	CcSEcCtD
Phenylpropanolamine—Constipation—Mitoxantrone—breast cancer	0.000369	0.00169	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Fluorouracil—breast cancer	0.000369	0.00169	CcSEcCtD
Phenylpropanolamine—Rash—Goserelin—breast cancer	0.000369	0.00169	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Thiotepa—breast cancer	0.000368	0.00168	CcSEcCtD
Phenylpropanolamine—Dermatitis—Goserelin—breast cancer	0.000368	0.00168	CcSEcCtD
Phenylpropanolamine—Somnolence—Fluorouracil—breast cancer	0.000368	0.00168	CcSEcCtD
Phenylpropanolamine—Anxiety—Paclitaxel—breast cancer	0.000366	0.00167	CcSEcCtD
Phenylpropanolamine—Nausea—Tamoxifen—breast cancer	0.000364	0.00166	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Capecitabine—breast cancer	0.000363	0.00166	CcSEcCtD
Phenylpropanolamine—Constipation—Gemcitabine—breast cancer	0.00036	0.00164	CcSEcCtD
Phenylpropanolamine—Ataxia—Doxorubicin—breast cancer	0.000356	0.00163	CcSEcCtD
Phenylpropanolamine—Nausea—Melphalan—breast cancer	0.000356	0.00163	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Irinotecan—breast cancer	0.000356	0.00163	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Mitoxantrone—breast cancer	0.000356	0.00163	CcSEcCtD
Phenylpropanolamine—Confusional state—Paclitaxel—breast cancer	0.000355	0.00162	CcSEcCtD
Phenylpropanolamine—Tranylcypromine—CYP2D6—breast cancer	0.000348	0.0515	CrCbGaD
Phenylpropanolamine—Nausea—Goserelin—breast cancer	0.000347	0.00159	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Gemcitabine—breast cancer	0.000347	0.00158	CcSEcCtD
Phenylpropanolamine—Dizziness—Vinorelbine—breast cancer	0.000346	0.00158	CcSEcCtD
Phenylpropanolamine—Tachycardia—Paclitaxel—breast cancer	0.000344	0.00157	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Fluorouracil—breast cancer	0.000341	0.00156	CcSEcCtD
Phenylpropanolamine—Drowsiness—Methotrexate—breast cancer	0.000337	0.00154	CcSEcCtD
Phenylpropanolamine—Vision blurred—Capecitabine—breast cancer	0.000334	0.00153	CcSEcCtD
Phenylpropanolamine—Vomiting—Vinorelbine—breast cancer	0.000333	0.00152	CcSEcCtD
Phenylpropanolamine—Tremor—Capecitabine—breast cancer	0.000332	0.00152	CcSEcCtD
Phenylpropanolamine—Dizziness—Thiotepa—breast cancer	0.000331	0.00151	CcSEcCtD
Phenylpropanolamine—Rash—Vinorelbine—breast cancer	0.00033	0.00151	CcSEcCtD
Phenylpropanolamine—Dermatitis—Vinorelbine—breast cancer	0.00033	0.00151	CcSEcCtD
Phenylpropanolamine—Hypotension—Paclitaxel—breast cancer	0.000329	0.0015	CcSEcCtD
Phenylpropanolamine—Insomnia—Paclitaxel—breast cancer	0.000319	0.00146	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Mitoxantrone—breast cancer	0.000318	0.00145	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Irinotecan—breast cancer	0.000318	0.00145	CcSEcCtD
Phenylpropanolamine—Vomiting—Thiotepa—breast cancer	0.000318	0.00145	CcSEcCtD
Phenylpropanolamine—Drowsiness—Epirubicin—breast cancer	0.000316	0.00144	CcSEcCtD
Phenylpropanolamine—Rash—Thiotepa—breast cancer	0.000315	0.00144	CcSEcCtD
Phenylpropanolamine—Dermatitis—Thiotepa—breast cancer	0.000315	0.00144	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Paclitaxel—breast cancer	0.000314	0.00144	CcSEcCtD
Phenylpropanolamine—Somnolence—Paclitaxel—breast cancer	0.000313	0.00143	CcSEcCtD
Phenylpropanolamine—Nausea—Vinorelbine—breast cancer	0.000311	0.00142	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Fluorouracil—breast cancer	0.000305	0.00139	CcSEcCtD
Phenylpropanolamine—Constipation—Paclitaxel—breast cancer	0.000301	0.00138	CcSEcCtD
Phenylpropanolamine—Confusional state—Docetaxel—breast cancer	0.000301	0.00138	CcSEcCtD
Phenylpropanolamine—Anxiety—Capecitabine—breast cancer	0.0003	0.00137	CcSEcCtD
Phenylpropanolamine—Tranylcypromine—CYP3A4—breast cancer	0.000299	0.0442	CrCbGaD
Phenylpropanolamine—Nausea—Thiotepa—breast cancer	0.000297	0.00136	CcSEcCtD
Phenylpropanolamine—Drowsiness—Doxorubicin—breast cancer	0.000292	0.00134	CcSEcCtD
Phenylpropanolamine—Phentermine—CYP2D6—breast cancer	0.000292	0.0431	CrCbGaD
Phenylpropanolamine—Confusional state—Capecitabine—breast cancer	0.000291	0.00133	CcSEcCtD
Phenylpropanolamine—Tachycardia—Docetaxel—breast cancer	0.000291	0.00133	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Paclitaxel—breast cancer	0.00029	0.00133	CcSEcCtD
Phenylpropanolamine—Dizziness—Irinotecan—breast cancer	0.000286	0.00131	CcSEcCtD
Phenylpropanolamine—Tachycardia—Capecitabine—breast cancer	0.000282	0.00129	CcSEcCtD
Phenylpropanolamine—Benzyl alcohol—CYP2D6—breast cancer	0.000281	0.0416	CrCbGaD
Phenylpropanolamine—Hypotension—Docetaxel—breast cancer	0.000279	0.00128	CcSEcCtD
Phenylpropanolamine—Dextroamphetamine—CYP2D6—breast cancer	0.000278	0.0412	CrCbGaD
Phenylpropanolamine—Pseudoephedrine—CYP2D6—breast cancer	0.000277	0.0409	CrCbGaD
Phenylpropanolamine—Vomiting—Mitoxantrone—breast cancer	0.000275	0.00126	CcSEcCtD
Phenylpropanolamine—Vomiting—Irinotecan—breast cancer	0.000275	0.00126	CcSEcCtD
Phenylpropanolamine—Dizziness—Fluorouracil—breast cancer	0.000273	0.00125	CcSEcCtD
Phenylpropanolamine—Rash—Irinotecan—breast cancer	0.000272	0.00124	CcSEcCtD
Phenylpropanolamine—Rash—Mitoxantrone—breast cancer	0.000272	0.00124	CcSEcCtD
Phenylpropanolamine—Dermatitis—Mitoxantrone—breast cancer	0.000272	0.00124	CcSEcCtD
Phenylpropanolamine—Dermatitis—Irinotecan—breast cancer	0.000272	0.00124	CcSEcCtD
Phenylpropanolamine—Hypotension—Capecitabine—breast cancer	0.00027	0.00123	CcSEcCtD
Phenylpropanolamine—Insomnia—Docetaxel—breast cancer	0.00027	0.00123	CcSEcCtD
Phenylpropanolamine—Vomiting—Gemcitabine—breast cancer	0.000267	0.00122	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Docetaxel—breast cancer	0.000266	0.00122	CcSEcCtD
Phenylpropanolamine—Somnolence—Docetaxel—breast cancer	0.000265	0.00121	CcSEcCtD
Phenylpropanolamine—Rash—Gemcitabine—breast cancer	0.000265	0.00121	CcSEcCtD
Phenylpropanolamine—Dermatitis—Gemcitabine—breast cancer	0.000265	0.00121	CcSEcCtD
Phenylpropanolamine—Flushing—Epirubicin—breast cancer	0.000263	0.0012	CcSEcCtD
Phenylpropanolamine—Vomiting—Fluorouracil—breast cancer	0.000263	0.0012	CcSEcCtD
Phenylpropanolamine—Insomnia—Capecitabine—breast cancer	0.000261	0.00119	CcSEcCtD
Phenylpropanolamine—Rash—Fluorouracil—breast cancer	0.000261	0.00119	CcSEcCtD
Phenylpropanolamine—Dermatitis—Fluorouracil—breast cancer	0.000261	0.00119	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Paclitaxel—breast cancer	0.000259	0.00119	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Capecitabine—breast cancer	0.000258	0.00118	CcSEcCtD
Phenylpropanolamine—Nausea—Irinotecan—breast cancer	0.000256	0.00117	CcSEcCtD
Phenylpropanolamine—Nausea—Mitoxantrone—breast cancer	0.000256	0.00117	CcSEcCtD
Phenylpropanolamine—Constipation—Docetaxel—breast cancer	0.000255	0.00117	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Epirubicin—breast cancer	0.000253	0.00116	CcSEcCtD
Phenylpropanolamine—Nausea—Gemcitabine—breast cancer	0.00025	0.00114	CcSEcCtD
Phenylpropanolamine—Vision blurred—Methotrexate—breast cancer	0.000248	0.00114	CcSEcCtD
Phenylpropanolamine—Constipation—Capecitabine—breast cancer	0.000247	0.00113	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Docetaxel—breast cancer	0.000246	0.00112	CcSEcCtD
Phenylpropanolamine—Nausea—Fluorouracil—breast cancer	0.000246	0.00112	CcSEcCtD
Phenylpropanolamine—Flushing—Doxorubicin—breast cancer	0.000243	0.00111	CcSEcCtD
Phenylpropanolamine—Tension—Epirubicin—breast cancer	0.000242	0.00111	CcSEcCtD
Phenylpropanolamine—Benzyl alcohol—CYP3A4—breast cancer	0.000241	0.0357	CrCbGaD
Phenylpropanolamine—Nervousness—Epirubicin—breast cancer	0.00024	0.0011	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Capecitabine—breast cancer	0.000238	0.00109	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Doxorubicin—breast cancer	0.000234	0.00107	CcSEcCtD
Phenylpropanolamine—Dizziness—Paclitaxel—breast cancer	0.000233	0.00106	CcSEcCtD
Phenylpropanolamine—Vision blurred—Epirubicin—breast cancer	0.000232	0.00106	CcSEcCtD
Phenylpropanolamine—Agitation—Epirubicin—breast cancer	0.000227	0.00104	CcSEcCtD
Phenylpropanolamine—Amphetamine—CYP2D6—breast cancer	0.000224	0.0332	CrCbGaD
Phenylpropanolamine—Tension—Doxorubicin—breast cancer	0.000224	0.00102	CcSEcCtD
Phenylpropanolamine—Vomiting—Paclitaxel—breast cancer	0.000224	0.00102	CcSEcCtD
Phenylpropanolamine—Rash—Paclitaxel—breast cancer	0.000222	0.00102	CcSEcCtD
Phenylpropanolamine—Dermatitis—Paclitaxel—breast cancer	0.000222	0.00101	CcSEcCtD
Phenylpropanolamine—Nervousness—Doxorubicin—breast cancer	0.000222	0.00101	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Docetaxel—breast cancer	0.00022	0.00101	CcSEcCtD
Phenylpropanolamine—Confusional state—Methotrexate—breast cancer	0.000217	0.000992	CcSEcCtD
Phenylpropanolamine—MAOA—nipple—breast cancer	0.000216	0.0573	CbGeAlD
Phenylpropanolamine—Vision blurred—Doxorubicin—breast cancer	0.000215	0.000983	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Capecitabine—breast cancer	0.000213	0.000973	CcSEcCtD
Phenylpropanolamine—Agitation—Doxorubicin—breast cancer	0.00021	0.000959	CcSEcCtD
Phenylpropanolamine—Anxiety—Epirubicin—breast cancer	0.000209	0.000957	CcSEcCtD
Phenylpropanolamine—Nausea—Paclitaxel—breast cancer	0.000209	0.000956	CcSEcCtD
Phenylpropanolamine—Methamphetamine—CYP2D6—breast cancer	0.000208	0.0307	CrCbGaD
Phenylpropanolamine—Phenelzine—CYP3A4—breast cancer	0.000204	0.0302	CrCbGaD
Phenylpropanolamine—Confusional state—Epirubicin—breast cancer	0.000203	0.000928	CcSEcCtD
Phenylpropanolamine—Hypotension—Methotrexate—breast cancer	0.000201	0.000919	CcSEcCtD
Phenylpropanolamine—Dizziness—Docetaxel—breast cancer	0.000197	0.000902	CcSEcCtD
Phenylpropanolamine—Tachycardia—Epirubicin—breast cancer	0.000197	0.000898	CcSEcCtD
Phenylpropanolamine—Insomnia—Methotrexate—breast cancer	0.000195	0.00089	CcSEcCtD
Phenylpropanolamine—Anxiety—Doxorubicin—breast cancer	0.000194	0.000885	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Methotrexate—breast cancer	0.000192	0.000877	CcSEcCtD
Phenylpropanolamine—Somnolence—Methotrexate—breast cancer	0.000191	0.000874	CcSEcCtD
Phenylpropanolamine—Dizziness—Capecitabine—breast cancer	0.000191	0.000874	CcSEcCtD
Phenylpropanolamine—Vomiting—Docetaxel—breast cancer	0.00019	0.000868	CcSEcCtD
Phenylpropanolamine—Rash—Docetaxel—breast cancer	0.000188	0.00086	CcSEcCtD
Phenylpropanolamine—Hypotension—Epirubicin—breast cancer	0.000188	0.00086	CcSEcCtD
Phenylpropanolamine—Dermatitis—Docetaxel—breast cancer	0.000188	0.00086	CcSEcCtD
Phenylpropanolamine—Confusional state—Doxorubicin—breast cancer	0.000188	0.000859	CcSEcCtD
Phenylpropanolamine—Vomiting—Capecitabine—breast cancer	0.000184	0.00084	CcSEcCtD
Phenylpropanolamine—Rash—Capecitabine—breast cancer	0.000182	0.000833	CcSEcCtD
Phenylpropanolamine—Insomnia—Epirubicin—breast cancer	0.000182	0.000832	CcSEcCtD
Phenylpropanolamine—Dermatitis—Capecitabine—breast cancer	0.000182	0.000832	CcSEcCtD
Phenylpropanolamine—Tachycardia—Doxorubicin—breast cancer	0.000182	0.000831	CcSEcCtD
Phenylpropanolamine—CYP1A2—nipple—breast cancer	0.00018	0.0478	CbGeAlD
Phenylpropanolamine—Dyspnoea—Epirubicin—breast cancer	0.00018	0.000821	CcSEcCtD
Phenylpropanolamine—Somnolence—Epirubicin—breast cancer	0.000179	0.000818	CcSEcCtD
Phenylpropanolamine—MAOA—embryo—breast cancer	0.000178	0.0473	CbGeAlD
Phenylpropanolamine—Nausea—Docetaxel—breast cancer	0.000177	0.000811	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Methotrexate—breast cancer	0.000177	0.00081	CcSEcCtD
Phenylpropanolamine—Hypotension—Doxorubicin—breast cancer	0.000174	0.000796	CcSEcCtD
Phenylpropanolamine—Constipation—Epirubicin—breast cancer	0.000172	0.000787	CcSEcCtD
Phenylpropanolamine—Nausea—Capecitabine—breast cancer	0.000172	0.000785	CcSEcCtD
Phenylpropanolamine—Insomnia—Doxorubicin—breast cancer	0.000168	0.00077	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Doxorubicin—breast cancer	0.000166	0.000759	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Epirubicin—breast cancer	0.000166	0.000758	CcSEcCtD
Phenylpropanolamine—Somnolence—Doxorubicin—breast cancer	0.000166	0.000757	CcSEcCtD
Phenylpropanolamine—ADRA2A—nipple—breast cancer	0.000166	0.044	CbGeAlD
Phenylpropanolamine—Constipation—Doxorubicin—breast cancer	0.000159	0.000728	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Methotrexate—breast cancer	0.000159	0.000725	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Doxorubicin—breast cancer	0.000154	0.000702	CcSEcCtD
Phenylpropanolamine—ADRB1—adipose tissue—breast cancer	0.00015	0.0398	CbGeAlD
Phenylpropanolamine—Hypersensitivity—Epirubicin—breast cancer	0.000148	0.000678	CcSEcCtD
Phenylpropanolamine—ADRA1A—epithelium—breast cancer	0.000147	0.039	CbGeAlD
Phenylpropanolamine—Dizziness—Methotrexate—breast cancer	0.000142	0.00065	CcSEcCtD
Phenylpropanolamine—ADRB1—female reproductive system—breast cancer	0.000138	0.0366	CbGeAlD
Phenylpropanolamine—Hypersensitivity—Doxorubicin—breast cancer	0.000137	0.000627	CcSEcCtD
Phenylpropanolamine—Vomiting—Methotrexate—breast cancer	0.000137	0.000625	CcSEcCtD
Phenylpropanolamine—Rash—Methotrexate—breast cancer	0.000136	0.00062	CcSEcCtD
Phenylpropanolamine—Dermatitis—Methotrexate—breast cancer	0.000136	0.00062	CcSEcCtD
Phenylpropanolamine—Dizziness—Epirubicin—breast cancer	0.000133	0.000609	CcSEcCtD
Phenylpropanolamine—MAOA—endometrium—breast cancer	0.00013	0.0346	CbGeAlD
Phenylpropanolamine—Vomiting—Epirubicin—breast cancer	0.000128	0.000585	CcSEcCtD
Phenylpropanolamine—Nausea—Methotrexate—breast cancer	0.000128	0.000584	CcSEcCtD
Phenylpropanolamine—Rash—Epirubicin—breast cancer	0.000127	0.00058	CcSEcCtD
Phenylpropanolamine—Dermatitis—Epirubicin—breast cancer	0.000127	0.00058	CcSEcCtD
Phenylpropanolamine—Dizziness—Doxorubicin—breast cancer	0.000123	0.000563	CcSEcCtD
Phenylpropanolamine—MAOA—uterus—breast cancer	0.00012	0.0319	CbGeAlD
Phenylpropanolamine—Nausea—Epirubicin—breast cancer	0.00012	0.000547	CcSEcCtD
Phenylpropanolamine—ADRA1A—adipose tissue—breast cancer	0.000118	0.0315	CbGeAlD
Phenylpropanolamine—Vomiting—Doxorubicin—breast cancer	0.000118	0.000541	CcSEcCtD
Phenylpropanolamine—MAOA—pituitary gland—breast cancer	0.000118	0.0313	CbGeAlD
Phenylpropanolamine—Rash—Doxorubicin—breast cancer	0.000117	0.000537	CcSEcCtD
Phenylpropanolamine—MAOA—adipose tissue—breast cancer	0.000117	0.0312	CbGeAlD
Phenylpropanolamine—Dermatitis—Doxorubicin—breast cancer	0.000117	0.000536	CcSEcCtD
Phenylpropanolamine—SLC6A2—female reproductive system—breast cancer	0.000117	0.0311	CbGeAlD
Phenylpropanolamine—ADRB1—endocrine gland—breast cancer	0.000117	0.031	CbGeAlD
Phenylpropanolamine—SLC6A2—adrenal gland—breast cancer	0.000114	0.0304	CbGeAlD
Phenylpropanolamine—Nausea—Doxorubicin—breast cancer	0.000111	0.000506	CcSEcCtD
Phenylpropanolamine—MAOA—female reproductive system—breast cancer	0.000108	0.0287	CbGeAlD
Phenylpropanolamine—ADRA1A—adrenal gland—breast cancer	0.000106	0.0282	CbGeAlD
Phenylpropanolamine—MAOA—adrenal gland—breast cancer	0.000105	0.028	CbGeAlD
Phenylpropanolamine—ADRA2A—endometrium—breast cancer	0.0001	0.0266	CbGeAlD
Phenylpropanolamine—SLC6A2—endocrine gland—breast cancer	9.91e-05	0.0263	CbGeAlD
Phenylpropanolamine—MAOA—female gonad—breast cancer	9.82e-05	0.0261	CbGeAlD
Phenylpropanolamine—ADRA1A—endocrine gland—breast cancer	9.22e-05	0.0245	CbGeAlD
Phenylpropanolamine—ADRA2A—uterus—breast cancer	9.21e-05	0.0245	CbGeAlD
Phenylpropanolamine—MAOA—endocrine gland—breast cancer	9.13e-05	0.0243	CbGeAlD
Phenylpropanolamine—ADRA2A—pituitary gland—breast cancer	9.05e-05	0.024	CbGeAlD
Phenylpropanolamine—ADRA2A—adipose tissue—breast cancer	9.01e-05	0.0239	CbGeAlD
Phenylpropanolamine—ADRA2A—female reproductive system—breast cancer	8.28e-05	0.022	CbGeAlD
Phenylpropanolamine—ADRA2A—adrenal gland—breast cancer	8.08e-05	0.0215	CbGeAlD
Phenylpropanolamine—CYP1A2—endocrine gland—breast cancer	7.62e-05	0.0202	CbGeAlD
Phenylpropanolamine—ADRA2A—female gonad—breast cancer	7.54e-05	0.02	CbGeAlD
Phenylpropanolamine—ADRA2A—endocrine gland—breast cancer	7.01e-05	0.0186	CbGeAlD
Phenylpropanolamine—SLC6A2—lymph node—breast cancer	6.85e-05	0.0182	CbGeAlD
Phenylpropanolamine—MAOA—lymph node—breast cancer	6.31e-05	0.0168	CbGeAlD
Phenylpropanolamine—ADRA2A—lymph node—breast cancer	4.84e-05	0.0129	CbGeAlD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	8.89e-06	4.37e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—FN1—breast cancer	8.88e-06	4.37e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—KRAS—breast cancer	8.84e-06	4.35e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CYP1B1—breast cancer	8.78e-06	4.32e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—NFKBIA—breast cancer	8.78e-06	4.32e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—LEP—breast cancer	8.75e-06	4.31e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—NOS3—breast cancer	8.72e-06	4.29e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—NOTCH1—breast cancer	8.69e-06	4.28e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CAV1—breast cancer	8.67e-06	4.27e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—HSP90AA1—breast cancer	8.61e-06	4.24e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CXCL8—breast cancer	8.6e-06	4.23e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—KDR—breast cancer	8.57e-06	4.22e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—HRAS—breast cancer	8.55e-06	4.21e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—NOS3—breast cancer	8.53e-06	4.2e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—KIT—breast cancer	8.5e-06	4.18e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PIK3CG—breast cancer	8.5e-06	4.18e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—APC—breast cancer	8.5e-06	4.18e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CDKN1B—breast cancer	8.4e-06	4.14e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—EGF—breast cancer	8.4e-06	4.13e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—NCOA1—breast cancer	8.38e-06	4.12e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—ESR1—breast cancer	8.35e-06	4.11e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—AKT1—breast cancer	8.31e-06	4.09e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—PIK3CA—breast cancer	8.31e-06	4.09e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PIK3CD—breast cancer	8.3e-06	4.09e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MDM2—breast cancer	8.27e-06	4.07e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—STK11—breast cancer	8.26e-06	4.06e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CYP19A1—breast cancer	8.26e-06	4.06e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—FN1—breast cancer	8.25e-06	4.06e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—RAF1—breast cancer	8.24e-06	4.06e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CASP3—breast cancer	8.23e-06	4.05e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—IL2—breast cancer	8.22e-06	4.05e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—RELA—breast cancer	8.21e-06	4.04e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—ALB—breast cancer	8.2e-06	4.03e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—IL6—breast cancer	8.18e-06	4.03e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—ERBB2—breast cancer	8.16e-06	4.01e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—NFKBIA—breast cancer	8.15e-06	4.01e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—MAPK3—breast cancer	8.14e-06	4.01e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—PIK3CA—breast cancer	8.12e-06	4e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MDM2—breast cancer	8.09e-06	3.98e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—NOTCH1—breast cancer	8.08e-06	3.97e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—RAF1—breast cancer	8.06e-06	3.97e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PIK3CB—breast cancer	8.05e-06	3.96e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MTOR—breast cancer	8.05e-06	3.96e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—RELA—breast cancer	8.03e-06	3.95e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CCND1—breast cancer	8.02e-06	3.94e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—JUN—breast cancer	8e-06	3.94e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—BRAF—breast cancer	7.99e-06	3.93e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—ERBB2—breast cancer	7.98e-06	3.93e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CTNNB1—breast cancer	7.94e-06	3.91e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PIK3CG—breast cancer	7.9e-06	3.89e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—KIT—breast cancer	7.9e-06	3.89e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—APC—breast cancer	7.9e-06	3.89e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PIK3CB—breast cancer	7.87e-06	3.87e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MTOR—breast cancer	7.87e-06	3.87e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—NOS3—breast cancer	7.84e-06	3.86e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—EGF—breast cancer	7.81e-06	3.84e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IGF1—breast cancer	7.78e-06	3.83e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MMP9—breast cancer	7.78e-06	3.83e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—AKT2—breast cancer	7.78e-06	3.83e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CDKN1A—breast cancer	7.75e-06	3.82e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—breast cancer	7.75e-06	3.81e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—EGFR—breast cancer	7.74e-06	3.81e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PTEN—breast cancer	7.74e-06	3.81e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CXCL8—breast cancer	7.73e-06	3.81e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—HRAS—breast cancer	7.68e-06	3.78e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—COMT—breast cancer	7.68e-06	3.78e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GSTP1—breast cancer	7.64e-06	3.76e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MAPK8—breast cancer	7.57e-06	3.72e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CXCL8—breast cancer	7.57e-06	3.72e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—MAPK3—breast cancer	7.56e-06	3.72e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CDKN1B—breast cancer	7.55e-06	3.72e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—AKT1—breast cancer	7.55e-06	3.71e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—HMOX1—breast cancer	7.53e-06	3.71e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—ITPR1—breast cancer	7.52e-06	3.7e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—HRAS—breast cancer	7.52e-06	3.7e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—AKT1—breast cancer	7.47e-06	3.68e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PIK3CD—breast cancer	7.47e-06	3.68e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—BRAF—breast cancer	7.42e-06	3.65e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CASP3—breast cancer	7.4e-06	3.64e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—PIK3CA—breast cancer	7.4e-06	3.64e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—IL2—breast cancer	7.39e-06	3.64e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—SERPINE1—breast cancer	7.39e-06	3.64e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CDKN1B—breast cancer	7.39e-06	3.64e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—IL6—breast cancer	7.35e-06	3.62e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—KRAS—breast cancer	7.31e-06	3.6e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—AKT1—breast cancer	7.31e-06	3.6e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CASP3—breast cancer	7.24e-06	3.56e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PIK3CB—breast cancer	7.24e-06	3.56e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—ABCB1—breast cancer	7.23e-06	3.56e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—IL2—breast cancer	7.23e-06	3.56e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IGF1—breast cancer	7.23e-06	3.56e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—AKT2—breast cancer	7.23e-06	3.56e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CCND1—breast cancer	7.21e-06	3.55e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—IL6—breast cancer	7.19e-06	3.54e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—EGFR—breast cancer	7.19e-06	3.54e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—JUN—breast cancer	7.19e-06	3.54e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—SRC—breast cancer	7.17e-06	3.53e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PTGS2—breast cancer	7.17e-06	3.53e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CTNNB1—breast cancer	7.14e-06	3.51e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—TYMS—breast cancer	7.1e-06	3.5e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—NOS3—breast cancer	7.06e-06	3.47e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CCND1—breast cancer	7.05e-06	3.47e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—JUN—breast cancer	7.03e-06	3.46e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PLA2G4A—breast cancer	7.02e-06	3.46e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GSTM1—breast cancer	7.02e-06	3.46e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—NCOR1—breast cancer	7.02e-06	3.46e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MMP9—breast cancer	7e-06	3.44e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—VEGFA—breast cancer	6.99e-06	3.44e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CTNNB1—breast cancer	6.98e-06	3.44e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CDKN1A—breast cancer	6.97e-06	3.43e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PTEN—breast cancer	6.96e-06	3.42e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PIK3CD—breast cancer	6.94e-06	3.42e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—STAT3—breast cancer	6.92e-06	3.41e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—PIK3CA—breast cancer	6.88e-06	3.38e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—SERPINE1—breast cancer	6.87e-06	3.38e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MMP9—breast cancer	6.84e-06	3.37e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CDKN1A—breast cancer	6.82e-06	3.36e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MAPK8—breast cancer	6.8e-06	3.35e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PTEN—breast cancer	6.8e-06	3.35e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—KRAS—breast cancer	6.8e-06	3.34e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—AKT1—breast cancer	6.79e-06	3.34e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GPX1—breast cancer	6.72e-06	3.31e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—PIK3CA—breast cancer	6.72e-06	3.31e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MDM2—breast cancer	6.69e-06	3.29e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—RAF1—breast cancer	6.67e-06	3.28e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CYP1A1—breast cancer	6.66e-06	3.28e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MAPK8—breast cancer	6.66e-06	3.28e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—RELA—breast cancer	6.64e-06	3.27e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—AKT1—breast cancer	6.64e-06	3.27e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MAPK3—breast cancer	6.61e-06	3.25e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—PIK3CA—breast cancer	6.6e-06	3.25e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—ERCC2—breast cancer	6.6e-06	3.25e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—ERBB2—breast cancer	6.6e-06	3.25e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—NOS3—breast cancer	6.56e-06	3.23e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MTOR—breast cancer	6.51e-06	3.21e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PIK3CB—breast cancer	6.51e-06	3.21e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—SRC—breast cancer	6.45e-06	3.17e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MYC—breast cancer	6.43e-06	3.16e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—TGFB1—breast cancer	6.41e-06	3.16e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—SRC—breast cancer	6.31e-06	3.11e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—EGFR—breast cancer	6.29e-06	3.09e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—VEGFA—breast cancer	6.28e-06	3.09e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CXCL8—breast cancer	6.26e-06	3.08e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PTEN—breast cancer	6.25e-06	3.08e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—PIK3CA—breast cancer	6.24e-06	3.07e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—STAT3—breast cancer	6.22e-06	3.06e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MDM2—breast cancer	6.22e-06	3.06e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—HRAS—breast cancer	6.22e-06	3.06e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—MTHFR—breast cancer	6.2e-06	3.05e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—RAF1—breast cancer	6.2e-06	3.05e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—RELA—breast cancer	6.17e-06	3.04e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—VEGFA—breast cancer	6.15e-06	3.02e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—ERBB2—breast cancer	6.13e-06	3.02e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CDKN1B—breast cancer	6.11e-06	3.01e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—STAT3—breast cancer	6.08e-06	2.99e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PIK3CB—breast cancer	6.05e-06	2.98e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MTOR—breast cancer	6.05e-06	2.98e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—AKT1—breast cancer	6.05e-06	2.98e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CASP3—breast cancer	5.99e-06	2.95e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IL2—breast cancer	5.98e-06	2.94e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—IL6—breast cancer	5.95e-06	2.93e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MAPK3—breast cancer	5.94e-06	2.92e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—KRAS—breast cancer	5.94e-06	2.92e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CCND1—breast cancer	5.83e-06	2.87e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—JUN—breast cancer	5.82e-06	2.86e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CXCL8—breast cancer	5.81e-06	2.86e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MAPK3—breast cancer	5.81e-06	2.86e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MYC—breast cancer	5.78e-06	2.84e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—HRAS—breast cancer	5.78e-06	2.84e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CTNNB1—breast cancer	5.77e-06	2.84e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—TGFB1—breast cancer	5.77e-06	2.84e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CAV1—breast cancer	5.72e-06	2.82e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CDKN1B—breast cancer	5.68e-06	2.79e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MMP9—breast cancer	5.66e-06	2.79e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MYC—breast cancer	5.65e-06	2.78e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—EGFR—breast cancer	5.65e-06	2.78e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CDKN1A—breast cancer	5.64e-06	2.78e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—TGFB1—breast cancer	5.64e-06	2.78e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PTEN—breast cancer	5.63e-06	2.77e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—AKT1—breast cancer	5.62e-06	2.76e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CASP3—breast cancer	5.57e-06	2.74e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IL2—breast cancer	5.56e-06	2.73e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—EGFR—breast cancer	5.53e-06	2.72e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—IL6—breast cancer	5.53e-06	2.72e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MAPK8—breast cancer	5.51e-06	2.71e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—AKT1—breast cancer	5.49e-06	2.7e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	5.47e-06	2.69e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PIK3CA—breast cancer	5.46e-06	2.69e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CCND1—breast cancer	5.42e-06	2.67e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—JUN—breast cancer	5.41e-06	2.66e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—AKT1—breast cancer	5.39e-06	2.65e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CTNNB1—breast cancer	5.36e-06	2.64e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—KRAS—breast cancer	5.34e-06	2.63e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—TP53—breast cancer	5.28e-06	2.6e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MMP9—breast cancer	5.26e-06	2.59e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CDKN1A—breast cancer	5.24e-06	2.58e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PTEN—breast cancer	5.23e-06	2.57e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—KRAS—breast cancer	5.22e-06	2.57e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—SRC—breast cancer	5.22e-06	2.57e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PIK3CG—breast cancer	5.21e-06	2.57e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MAPK8—breast cancer	5.12e-06	2.52e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—AKT1—breast cancer	5.1e-06	2.51e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—VEGFA—breast cancer	5.08e-06	2.5e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—HRAS—breast cancer	5.05e-06	2.49e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—STAT3—breast cancer	5.03e-06	2.48e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PIK3CA—breast cancer	4.91e-06	2.41e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—SRC—breast cancer	4.85e-06	2.39e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—IL6—breast cancer	4.83e-06	2.38e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MAPK3—breast cancer	4.81e-06	2.37e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PIK3CA—breast cancer	4.8e-06	2.36e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—TP53—breast cancer	4.75e-06	2.34e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—VEGFA—breast cancer	4.72e-06	2.32e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MYC—breast cancer	4.68e-06	2.3e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—STAT3—breast cancer	4.68e-06	2.3e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—TGFB1—breast cancer	4.67e-06	2.3e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—TP53—breast cancer	4.64e-06	2.29e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PIK3CD—breast cancer	4.58e-06	2.26e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—EGFR—breast cancer	4.57e-06	2.25e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—HRAS—breast cancer	4.54e-06	2.23e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—ALB—breast cancer	4.52e-06	2.23e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MAPK3—breast cancer	4.47e-06	2.2e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—AKT1—breast cancer	4.46e-06	2.19e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—HRAS—breast cancer	4.44e-06	2.19e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PIK3CA—breast cancer	4.41e-06	2.17e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MYC—breast cancer	4.35e-06	2.14e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—IL6—breast cancer	4.34e-06	2.14e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TGFB1—breast cancer	4.33e-06	2.13e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—NOS3—breast cancer	4.33e-06	2.13e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—KRAS—breast cancer	4.32e-06	2.13e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—IL6—breast cancer	4.25e-06	2.09e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—EGFR—breast cancer	4.25e-06	2.09e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—KRAS—breast cancer	4.01e-06	1.98e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—AKT1—breast cancer	4.01e-06	1.97e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PIK3CB—breast cancer	3.99e-06	1.97e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PIK3CA—breast cancer	3.97e-06	1.95e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PTGS2—breast cancer	3.96e-06	1.95e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—AKT1—breast cancer	3.92e-06	1.93e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—TP53—breast cancer	3.84e-06	1.89e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PIK3CA—breast cancer	3.69e-06	1.82e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—HRAS—breast cancer	3.67e-06	1.81e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—AKT1—breast cancer	3.6e-06	1.77e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TP53—breast cancer	3.57e-06	1.76e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IL6—breast cancer	3.52e-06	1.73e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PTEN—breast cancer	3.45e-06	1.7e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—HRAS—breast cancer	3.41e-06	1.68e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IL6—breast cancer	3.27e-06	1.61e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—AKT1—breast cancer	3.24e-06	1.6e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—AKT1—breast cancer	3.01e-06	1.48e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PIK3CA—breast cancer	2.44e-06	1.2e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—AKT1—breast cancer	1.99e-06	9.79e-06	CbGpPWpGaD
